SEC.04 // [TRIAL ENDPOINTS]
Tesamorelin Research: What the Visceral-Fat Trials Measured
Every endpoint logged to its study — the visceral-fat and liver-fat numbers, the predictors of response, and the reversal on discontinuation.
The short version
This page is the tesamorelin research record laid out endpoint by endpoint. In people with HIV-associated fat redistribution, tesamorelin shrank the deep belly fat (visceral fat) by about 15% in six months and kept it off for a year of dosing, while leaving the fat under the skin and overall weight mostly alone. It also lowered fat inside the liver. The catch: the fat came back when people stopped, and almost all of this was studied in one population — adults with HIV. Outside that group, the evidence is thin. Each number below is tied to the study that produced it.
Studied effects of tesamorelin
The studied effects of tesamorelin cluster around one outcome: selective reduction of visceral adipose tissue. In the pivotal 26-week trial of 412 HIV patients, tesamorelin 2 mg/day reduced visceral fat by 15.2% while placebo increased it by 5.0%; triglycerides fell 50 mg/dL (versus +9 mg/dL on placebo) and IGF-1 rose 81.0% [1]. A JAMA trial of 50 antiretroviral-treated adults reported a visceral-fat treatment effect of -42 cm2 (P=0.005) [3]. A 2026 meta-analysis of five randomized trials pooled the visceral-fat reduction at a mean difference of -27.71 cm2 (95% CI -38.37 to -17.06; P<0.001), trunk fat at -1.18 kg, and lean body mass at +1.42 kg [15].
A 2021 analysis added a quality dimension: over 26 weeks tesamorelin raised visceral- and subcutaneous-fat density on CT (VAT +6.2 vs +0.3 HU placebo, P<0.0001), indicating improved adipocyte quality independent of the change in fat quantity [12].
What the trials measured before and after 26 to 52 weeks
Framed as trial endpoints rather than personal photos, the tesamorelin before and after picture is a set of imaging measurements at fixed timepoints. Before-to-after at 26 weeks: visceral fat -15.2% versus a 5.0% increase on placebo [1]. Before-to-after at 52 weeks: the reduction was sustained at roughly -18% from baseline (P<0.001), and glucose changes over the year were not clinically significant [2]. The endpoints were visceral adipose tissue on CT, triglycerides, and IGF-1 — not subjective appearance.
How long does it take to see fat loss from tesamorelin?
The pivotal trials measured significant visceral-fat reduction at 26 weeks, with further reduction sustained through 52 weeks of continued dosing [1][2]. A pooled analysis found no predictors of response identifiable at the 3-month mark — the separating signal appeared later [13].
Liver-fat findings
Tesamorelin lowered measured liver fat in HIV trials. In the 6-month JAMA RCT, it reduced hepatic lipid-to-water percentage by a net -2.9% (P=0.003) alongside the -42 cm2 visceral-fat effect [3]. A 2026 meta-analysis reported a pooled hepatic-fat-fraction reduction of -4.28% [15]. A transcriptomic analysis of liver tissue from HIV patients with NAFLD treated for 12 months found upregulated oxidative-phosphorylation gene sets and downregulated inflammatory and tissue-remodeling pathways — a mechanistic correlate for the hepatic-fat benefit consistent with GH/IGF-1-driven visceral lipolysis rather than a direct hepatic drug action [6].
The liver result is one of the more interesting threads in the tesamorelin record because the mechanism appears to be indirect. The drug acts on the pituitary and the visceral fat; the liver benefit seems to follow from the visceral-fat reduction rather than from any direct action on liver cells. The transcriptomic signature supports that reading — genes governing how mitochondria burn fuel went up, while inflammatory and scarring pathways went down [6], the molecular shape of a liver unloading fat rather than one being directly drugged. As with every other endpoint here, this was measured in HIV-associated fatty liver, and extending it to general metabolic-dysfunction-associated steatotic liver disease remains investigational [3][15].
How does tesamorelin affect the liver in NAFLD?
It lowered measured hepatic fat in HIV trials, and a liver-tissue transcriptomic analysis found upregulated oxidative-phosphorylation genes with downregulated inflammatory pathways [3][6]. The pattern is consistent with visceral-fat lipolysis driving the liver benefit, not a direct drug action on hepatocytes.
Is tesamorelin a potential treatment for non-alcoholic fatty liver disease?
In the 6-month JAMA RCT in HIV adults, tesamorelin reduced hepatic lipid-to-water percentage by a net -2.9% (P=0.003) [3]. NAFLD/MASLD use remains investigational and off-label; the data were generated in HIV-associated fatty liver, not the general population.
Can tesamorelin reduce liver fat?
In the JAMA HIV trial it produced a net -2.9% reduction in hepatic fat fraction (P=0.003) [3], and a 2026 meta-analysis reported a pooled hepatic-fat reduction of -4.28% [15]. Those reductions were studied in HIV-associated fatty liver, not in the general population.
Who responded, and what predicted it
A pooled analysis of two Phase 3 trials (543 tesamorelin versus 263 placebo) found the odds of reducing visceral fat below 140 cm2 were 3.9-fold greater with tesamorelin (95% CI 2.03-7.44); baseline metabolic syndrome, triglycerides above 1.7 mmol/L, and white race predicted response, with no predictors identifiable at 3 months [13]. A 2023 post-hoc analysis found the drug was equally effective at reducing visceral fat and waist circumference whether or not patients had dorsocervical fat accumulation (no significant subgroup difference, P=0.657) [14].
What happens when you stop taking tesamorelin?
In the 52-week program, visceral fat reaccumulated upon discontinuation; the measured benefits were contingent on continued dosing [2]. The reduction was a maintained state, not a permanent remodeling — stopping reversed it within weeks.
Will tesamorelin help me lose belly fat?
In HIV-associated lipodystrophy, tesamorelin 2 mg/day reduced visceral abdominal fat by 15.2% at 26 weeks versus a 5.0% increase on placebo [1]. Efficacy outside that studied population is not established by large randomized trials.
Does tesamorelin burn belly fat?
It selectively reduced visceral (intra-abdominal) fat in HIV trials by stimulating GH/IGF-1-mediated lipolysis; subcutaneous fat and BMI generally changed little [1]. The effect targets deep abdominal fat rather than total body weight.
Does tesamorelin work for fat loss in non-HIV users?
Non-HIV human data are limited to a mechanistic study in healthy men, in which the compound augmented pulsatile GH release and raised IGF-1 over two weeks [4][10]. No large general-population fat-loss randomized trial has been completed, so non-HIV efficacy is mechanistically plausible but unestablished and off-label.